Maxim Comments On OncoSec Medical As It Takes IL-12 Immunopulse To Head And Neck Cancer
Maxim Group analyst Jason Kolbert is out today with his second note this week on OncoSec Medical (OTC:ONCS) maintaining a Buy rating with a $3.00 price target, following today’s conference call where the company discussed plans to expand its IL-12 Immunopulse platform to Head and Neck Cancer.
Kolbert noted, “Why head and neck cancer? Like melanoma, this patient population has a high incidence of anti-PD-1 therapy non-responders. Oncosec’s intratumoral immunotherapy with IL-12 has been shown to increase ”Tumor-Infiltrating Lymphocytes’ (TILs) that kill tumor cells.”
The analyst concluded, “IL-12 Immunopulse upregulation of IL-12 in the tumor itself may be the key to ‘unmasking’ tumors to T cell attack, potentially further enhanced by increased susceptibility to checkpoint inhibitors like anti-PD-1 monoclonal antibodies. Oncosec’s approach may be applicable to many tumor types.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 4.5% and a 40.2% success rate. Kolbert has a -3.3% average return when recommending ONCS, and is ranked #759 out of 3401 analysts.